Dosing in Later-Line CRC Tx
Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

Released: October 21, 2021

Expiration: October 20, 2022

Kanwal Raghav
Kanwal Raghav, MD
Rachel Riechelmann
Rachel Riechelmann, MD, PhD

Activity

Progress
1
Course Completed

In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

  • Individualizing therapy
  • Clinical data and experience informing optimal dosing
  • Key adverse events